Corporate Restructuring FAQ

Who is Patient Square Capital?

  • Patient Square Capital is a health care investment firm based in Silicon Valley dedicated to funding differentiated companies in the health care industry.
  • Patient Square’s portfolio is valued at approximately $8 billion and includes investments in eleven private companies; all are focused on products and services that improve human health, including therapeutics, medical technologies, and health care services.

Why does Patient Square want to acquire NanoString?

  • Patient Square is attracted to NanoString for our technology portfolio, our great people, and our track record of serving customers in the scientific research community
  • They see tremendous value and potential in our spatial biology and gene expression businesses

What does this announcement mean for customers and employees?

  • Together, our victory in the European court and the agreement with Patient Square provides continuity for our customers and employees, ensuring that our market-leading platforms for spatial biology and gene expression will remain available. 

What does this mean for NanoString in connection with the Chapter 11 process?

  • Subject to bankruptcy court approval following an auction and completion of customary closing conditions, including the expiration of the 15-day waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, we expect the transaction to close in the second fiscal quarter of this year.
  • NanoString is thereafter expected to exit Chapter 11 and emerge with new investors, and the new private NanoString will operate in the ordinary course of business outside Chapter 11.